Antibodies are becoming more and more known and dominant in biopharmaceuticals ever since the introduction of the first therapeutic monoclonal antibodies in the 80s. Due to increased research in the development of medicine, technological advancements, investments in the health care system, and demand for biological substances for chronic diseases, more focus is now being given …
![]()





